What are the current treatment recommendations and unmet needs in early RRMM?
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
The Multiple Myeloma Hub was pleased to speak with Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked about the current treatment recommendations and unmet needs in early relapsed/refractory multiple myeloma (RRMM).
In this interview, Banerjee evaluates the latest advancements and unmet needs in the treatment of early RRMM, highlighting the approval of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.